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Wepresent here ourfirst results concerning the evaluation of hyaluronic acid (HA) as a candidate to formulate an
organic–mineral cement with sustained release properties. Incorporating drug-loaded microspheres in mineral
bone cements is an alternative strategy to improve their ability as drug delivery materials. To synthesize micro-
spheres according to a reproducible process and control at the same time their morphology and their encapsula-
tion efficiency is one of the main challenges of the conception of such drug-loaded bone substitute. In this
context, we investigated the potentialities of two HA, differing by their molecular weight, to formmicrospheres
by a spray-drying technique. Erythrosin B (EB) was encapsulated as a model drug and spray-drying process con-
ditionswere optimized. To perform this, the rheological behavior and viscosity of HA solutions have been related
to their spray-drying ability, and then to the resulting microparticles morphological properties and size distribu-
tion. Reproducible microspheres, answering to the requirements in terms of size and encapsulation efficiency,
have been obtained from both HA. However the HA exhibiting the lowest molecular weight, HA600, led to
smaller microparticles, with a higher polydispersity index. Their swelling ability, related to their stability upon
rehydration, also appeared reduced. In this context, HA850, with the highest molecular weight, was selected
and the possibility to modulate drug release by HA850 microspheres incorporation into a mineral cement was
explored. EB release kinetics from HA microspheres, HA microspheres loaded cement and reference cement
were followed at 37 °C, in Tris buffer at pH 7.4, using European Pharmacopoeia flow-through cells. Results
showed that HAmicrospheres incorporation into amineral cement permitted tomodify the cement drug release
profile and led to a sustained release.
1. Introduction
Hyaluronic acid (HA) is an abundant non-sulfated glycosamino-
glycan component of synovial fluid and extracellular matrices. It is
a mucopolysaccharide consisting of repeating units of D-glucuronic
acid and N-acetyl-D-glucosamine (Fig. 1). It is a well-known bio-
compatible, nonimmunogenic and biodegradable polymer, having
widespread applications in drug delivery, tissue engineering and
viscosupplementation [1–6]. Besides being an important structural
component in cartilage, HA is also essential for bone remodeling
[7]. HA is an attractive starting material for the construction of
bulk gels or hydrogel particles [8] but its applications in bone tissue
engineering are limited by its poor mechanical properties. For this
reason, it is often associated with calcium phosphates in order to
obtain reinforced and/or injectable bone cements, consisting in
HA gels containing hydroxyapatite [9,10] or calcium phosphate
cements CPCs containing HA [11,12].
To minimize the risk of post-operative failure, surgeons often
require the possibility to co-administer therapeutic agents and/or
biologically active components limiting inflammation, bacteria pro-
liferation or promoting bone reconstruction (antibiotics, growth
factors…). In this context, CPCs can be used as local drug delivery
systems [13,14]. An alternative approach for drug loading is to incor-
porate the drug in polymeric microspheres before blending with
CPC. This strategy offers two advantages: polymer microparticles
could help to modulate drug delivery [15–20], in combination with
cohesion and/or enhanced resorption and remodelling capability
[13,14].
Synthetic polymers, mainly poly(lactic-co-glycolic) acid PLGA, have
been tested for this purpose [15,16,20], but their acidic degradation
remains problematic. Surprisingly, polysaccharides have rarely been
exploited to form microparticles [18] although they are frequently
added to CPCs as rheological modifiers or cohesion promoters [21–23].
HA has never been tested for this purpose.
In this context, we decided to evaluate hyaluronic acid as a candidate
to formulate a loaded microspheres–mineral cement whose release
properties could be tailored on demand.
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To synthesizemicrospheres according to a reproducible process and
control at the same time their morphology and their encapsulation
efficiency is one of themain challenges of such organic–mineral cement
design. Process conditions have to be optimized to fit the desired parti-
cles characteristics: (i) high encapsulation efficiency, (ii) spherical mor-
phology, (iii) particles mean size and size distribution maintaining the
injectability property of the final organic–mineral cement.
In this context, we explored the potentialities of twoHA, differing by
their molecular weight, to form microspheres with a spray-drying
method. Spray-drying method consists of atomizing chemical solutions
into droplets dispersed and dried inside a carrier gas, which induces a
concentration of non-volatile species and the solidification of particles.
It is extensively used in pharmaceutical industries [24,25], since the
textural and release properties of the materials are highly tunable
thanks to the variation of the solution components.
Erythrosin B (EB), a fluorescein derivative, was encapsulated as a
model drug and spray-drying process conditions were optimized. To
perform this, the rheological behavior and viscosity of HA solutions
have been related to their spray drying ability, and then to the resulting
microparticles morphological properties and size distribution. Then the
release ability of a HAmicrospheres–mineral cementwas evaluated and
compared to themicrospheres and themineral cement release profiles.
2. Materials and methods
Two hyaluronic acid (HA) samples with high molecular weight
were tested in this study. HA600 (Cristalhyal, Soliance, France, kindly
provided by Pr R. Auzély-Velty from the CERMAV laboratory, Grenoble,
France) and HA850 (Primalhyal, Soliance, France) exhibited an average
molecular weight of 600,000 Da and 850,000 Da, respectively. Erythro-
sin B (Tetraiodofluorescein sodium salt, dye content 91.7%) was pur-
chased from Alfa Aesar and Tris (Tris(hydroxymethyl)aminomethane
Trizma® base BioXtra, purity ≥99.9%) from Sigma.
2.1. Preparation of HA and HA-EB solutions
Polymer solutions, with HA concentrations ranging from 1 g/L to
10 g/L, were obtained by dispersing polymer powder in deionized
water under continuous stirring for 24 hours at room temperature.
2.2. Rheological characterization of HA in solution
Polymers rheological behavior, at concentrations ranging from
1 g/L to 10 g/L, was studied using a controlled stress rheometer
(Haake Rheostress RS 75) equipped with a cone plate geometry
(6 cm diameter; 1° angle). Measurements were obtained with im-
posed shear rate ranging from 0 to 2000 s−1.
2.3. Production of HA microspheres: Spray-drying
Microparticleswere produced using a Buchimini Spray Dryermodel
190 (Buchi, Germany). Briefly, the polymer solutions, with HA concen-
trations ranging from 1 g/L to 6 g/L, were fed into the instrument by a
peristaltic pump and sprayed with a 0.7 mm nozzle, by means of a
flow of compressed air, in the drying chamber of the apparatus. A flow
of heated air aspirated by a pump induced the quick evaporation of
the solvent from the drops, leading to the formation of solidmicroparti-
cles. The instrumental settings are reported in Table 1. The obtained
particles, after separation from the exhausted air cyclone, settled into
a bottom collector and were kept in sealed tubes at ambient tempera-
ture prior use.
2.4. Microparticles characterization
Morphology (shape and surface) of the dried microspheres was
observed by scanning electron microscopy (SEM) using a LEO 435VP
microscope after metallization by silver coating under vacuum by SPI
Sputter coating unit.
Particles size distributionsweremeasured using a laser particle sizer
Mastersizer 2000 (Malvern, UK) based on a laser light scattering tech-
nique. Each sample was measured in triplicate. The volume weighted
mean diameters, (D [4,3]) and mean D(0.5), were used to describe the
particles size. The polydispersity or span of size distributions was eval-
uated by calculation of samples polydispersity index PI = [D(0.9) −
D(0.1)]/D(0.5)
2.4.1. Microparticles recovery: Yield
Microparticles recovery efficiencies were calculated as percentage
of weight of the obtained microparticles, taking as reference the total
amount of polymer (and EB if added) used for their preparation.
2.4.2. Drug content of microparticles: Encapsulation efficiency
The amount of encapsulated drug permilligramof driedmicrospheres
was determined by visible spectroscopy (Spectrophotometer HP 8451A)
at 528 nm (wavelength value corresponding to the λmax of EB), after
complete degradation (i.e. after 72 hours) of 100 mg of microspheres
into Tris buffer 0.1 M solution at pH 7.4, under stirring at 100 rpm at
room temperature. Encapsulation efficiency was calculated by the ratio
between this EB amount to the EB amount initially incorporated in the
polymer solution.
2.5. Preparation of reference and microspheres-loaded cements
The reference mineral cement (MC) paste was prepared by mixing
the appropriate amount of liquid phase (deionized water) with a pow-
der mixture of brushite (DCPD, CaHPO4, 2H2O) and vaterite (CaCO3), as
previously published [26]. Powder and liquid phase were mixed using
a liquid/solid weight ratio of 0.7. In the case of reference EB-cements
(MC-EB), EB was added in the solid phase. In the case of microspheres-
loaded cements (MC-HA-EB), the required amount of microspheres
(10% w/w of the solid phase of the cement) was added to the reference
paste after 1 minute of mixing, and mixed until visually homogeneous
distribution of the microparticles within the paste was obtained. The
pastes were then filled into silicone moulds, placed in sealed containers
and let at 37 °C in awater saturated atmosphere for 48 hours, while set-
ting and hardening.
Fig. 1. Chemical structure of the monomer units of hyaluronic acid (HA).
Table 1
Spray drying conditions. Spray-drying parameters of themicrospheresmanufactured (HA or
EB-loaded HA microspheres) for this study using a Büchi B-290 equipment.
Spray-dryer parameters HA600 HA600-EB HA850 HA850-EB
Atomizing gas flow rate (L/h) 357 357 357 357
Drying gas flow rate (L/h) 30 30 30 30
Feedstock flow rate (L/h) 0.34 0.34 0.34 0.34
Inlet temperature (°C) 120 120 120 120
Outlet temperature (°C) 55 59 57 65
2.6. Microspheres stability
Microspheres stability with time was evaluated by studying their
swelling in Tris buffer at pH 7.4. Swelling was estimated by weighing
microspheres at determined intervals of time after immersion into the
buffer, according to the equation:
Microspheres swelling at time t %ð Þ ¼ mt−m0ð Þ=m0½ % & 100
where mt is microspheres weight at time t, and m0 is microspheres
weight before immersion in buffer.
The procedure to perform this was standardized: a precise
amount of microspheres of approximately 100 mg was put in a filter
between glass beads and immersed in 10 mL of Tris buffer. At deter-
mined intervals of time, the buffer was removed by filtration under
vacuum (by using a vacuum pump during 20 seconds) and the
drained filter weighed. Then the experiment was carried on by im-
mersing again the microspheres in the same amount of fresh buffer,
until microspheres destructuration and complete gel erosion. This
experiment was done 3 times for each sample and results were
expressed as mean ± standard deviation.
2.7. In vitro release kinetics
2.7.1. Drug release conditions
Erythrosin B release profiles were obtained with a flow-through cell
system, USP Apparatus 4 (Sotax CE6, Sotax AG, Switzerland) with
22.6 mm cells and a piston pump (Sotax CY7, Sotax AG, Switzerland).
In all experiments laminar flow (with a bed of 5 g of glass beads) was
used. The in vitro release tests were carried out at 37 °C ± 0.5 °C
under sink conditions according to European Pharmacopoeia guidelines
[27]. About 100 mg of microspheres or a block of hardened cement of
about 1.5 g were placed above the glass beads and covered with 3 g
more. The dissolutionmedium, Tris buffer 0.1 M (pH 7.4), was pumped
through the column at a flow rate of 10 mL/min. A closed system was
used, recycling 500 mL of dissolution medium. Periodically, fractions
of 5 mLwere collected and the drug content was determined by visible
spectroscopy at 528 nm (Spectrophotometer HP 8451A), according to a
standard curve (EB concentrations ranging from 1 mg/L to 15 mg/L, co-
efficient of determination r2 = 0.9998). Same volume of dissolution
medium was replaced back after each sampling in order to maintain
sink conditions. For every trial, a standard curve was prepared. The
in vitro release studies were performed in triplicate. Results were
expressed as mean ± standard deviation.
2.7.2. Drug release analysis
The experimental release data were then fitted to the following
semi-empirical equations respectively describing (i) Higuchi model,
which is adapted to solid drugs dispersed in solid granular matrices
[28], (ii) Weibull model, which is adapted to heterogeneous systems
[29], and dissolutive release mechanism from microspheres [30].
Within Higuchi model, the ratio Q(t)/Q0 between the cumulative
percentage of drug released at time t and at infinite time is:
Q tð Þ=Q0 ¼ KH ' t
1=2
þ c ðiÞ
where KH is the dissolution constant, coefficient calculated by plotting
the linear forms of the Higuchi equation.
Within Weibull model, Q(t)/Q0 is:
Q tð Þ=Q0 ¼ 1−exp − t−tlag
! "b
=tscale
# $
ðiiÞ
where tlag is the lag time before drug release takes place, tscale is in-
dicative of the timescale for the release process and b characterizes
the shape of the release curve.
To put in evidence a dissolutive release mechanism, Q(t)/Q0 is
plotted according to the following equation:
Q tð Þ=Q0 ¼ KDiff ' t
0:432
þ c
′
ðiiiÞ
KDiff and c′ are coefficients calculated by plotting the linear forms of
the equation.
The release data up to the plateau of released drug were used to
produce theoretical release curves.
2.8. Statistical analysis
Results are expressed as mean ± standard deviation. Statistical
comparison of the data was performed using the t-test for comparison
between two groups or one-way ANOVA and post hoc Boferroni's test
for comparison of more than two groups. A value of p b 0.05 was
considered significant.
3. Results and discussion
Two hyaluronic acid samples HA600 and HA850, with different
average molecular weight, have been compared in order to determine
the best candidate to form microspheres to incorporate in a mineral
cement. The aimwas to obtainmicrospheres of about 5 to 30 μm to pre-
serve cement injectability, with the best yield. For this purpose, a spray-
drying method was chosen. Although the production of HA micro-
spheres by spray-drying has already been reported in the literature
[2,6,5], the operating conditions can vary and may affect particle size
and morphology. The choice of the HA type is also far from negligible
as its behavior in solution and its molecular weight will directly impact
the spray-drying process conditions, hence, microspheres morphology
and rehydration after drying. The presence of an active compound in
solution may also have an influence as it could modify in an
unpredictable manner the viscosity of the solution to spray-dry.
Moreover, the physico-chemical characteristics of the drug, in
particular its hydrophilic–lipophilic balance, play a crucial role on the
encapsulation efficiency value. In this study, our aim was to be in an
ideal case, with a model hydrophilic molecule able to diffuse freely
out of the microspheres, reference cement and composite. We decided
to work with a hydrophilic model molecule, erythrosine B (EB). EB is a
red fluorescent dye which can be easily assayed by fluorescence or
absorption in the visible range (λmax = 526–528 nm); its chemical
formula is presented in Fig. 2. At neutral pH it is positively charged,
avoiding the possibility of ionic interaction of the drug with themineral
phase of the cement in the dissolution–precipitation process taking
place during setting (resulting in Ca2+ ions chelation) and adsorption
on the components of the mineral cement.
Fig. 2. Chemical structure of erythrosin B (EB).
3.1. Optimization of the operating conditions of the spray drying process
Various parameters may influence microspheres morphology and
process yield. Some are directly correlated to the method: atomizing
gasflow rate, drying gasflow rate, feedstockflow rate, and inlet temper-
ature [24] (see Table 1 for the instrumental settings used in this study).
Others depend on the properties of the solutions to spray-dry. To
control this parameter, we decided to rely the rheological properties
of the HA solutions to their ability to be spray-dried. HA solutions of
concentrations ranging from 1 to 10 g/L have been characterized with
a rheometer before being spray-dried. The resulting microspheres
have been observed by SEM and their size distribution was determined.
As an example the results obtained for HA600 are shown in Fig. 3.
All the HA solutions exhibited a shear-thinning behavior and were
nonthixotropic. A concentration of 1 g/L appeared as the minimum
threshold of concentration to obtain microspheres, and a concentration
of 6 g/L resulted in too viscous solutions. Between these limits, HA
concentration did not seem to influence the resulting microspheres mor-
phology (Fig. 3). They look for themost part spherical, with a smooth sur-
face. However, their size distribution appeared correlated to the viscosity
of the initial HA solutions. Liu et al., who investigated the influence of
polymer concentration on the size and morphology of spray-dried chito-
sanmicroparticles, led to the same observations [31]. In our case, increas-
ing HA concentration increased particles sizes and spray-drying yield, by
decreasing the rate of small particles, which are more difficult to collect
and impact the polydispersity index (PI) of the batches. As a consequence,
HA concentration, in the range from1 to4 g/L, had a significant effect on
particle size, as demonstrated by statistical analysis (p b 0.05).
We explored the influence of HA type and EB presence on the
rheology of HA solutions, and their consecutive spray-dry-ability.
Concerning the influence of HA type, a comparison of the viscosities
of HA600 and HA850 solutions at 1000 s−1 is shown in Fig. 4. As
expected, increasing HA concentrations increased HA solutions
viscosity. The HA850 viscosity appeared higher but close to the one
of HA600 at low concentrations; however the phenomenon was re-
versed for concentrations higher than 5 g/L, perhaps due to smaller
chains entanglement. The results obtained in terms of morphology
and size distribution of the particles made us choose to work with
concentrations of 4 g/L, just below themaximum threshold of concentra-
tion allowing spray-drying. These conditions permitted to obtain HA
microspheres in a reproducible manner, with polydispersity indexes
lower than 3 for both HA tested (Table 2). Using spray-drying to produce
HAmicrospheres presents many advantages. In comparison with solvent
evaporation after emulsification, a competitor method to produce micro-
spheres, spray-drying results in a one-pot synthesis, avoiding time-
consuming steps and the use of harsh solvents [32]. It is compatible
Fig. 3. Rheological behavior of HA600 in solution and resulting microspheres characteristics after spray-drying: A) flow curves of HA solutions at various concentrations; B) resulting
microspheres morphological properties after spray-drying of the solutions: SEM micrographs and particle size distributions.
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Fig. 4. Evolution of the viscosity of HA solutions at 1000 s−1 as a function of polymer con-
centration and average molecular weight (●, dotted line: HA600;■, full line: HA850).
with on-line continuous production and easily scaled up, a necessity for
further industrial development.
Concerning the influence of EB on HA solutions, it resulted in a
decrease of the viscosity at 1000 s−1 of 6 to 10 mPa s, whatever the
HA molecular weight and the HA concentration tested. As an example,
the viscositiesmeasured for various concentrations of HA850, in presence
or absence of EB in solution, are shown in Fig. 5. As this decrease of viscos-
ity of HA solutions did not notably impact HA particles morphology, we
kept the same HA concentration of 4 g/L as operating condition for the
following HA-EB microspheres synthesis.
3.2. Microspheres characterization
Fig. 6 shows the morphology of the HA microparticles with or
without drug obtained with the optimized conditions. Table 2 reports
microspheres main characteristics (EB contents, encapsulation efficien-
cies and sizes).
High EB encapsulation efficiencies were obtained. In all cases, parti-
cles with a spherical morphology and a smooth surface were observed.
Their D(0.5) ranging from 8.8 to 28.1 μm remained compatible with the
injectability of the further polymer–mineral substitutes. However, HA
molecular weight influence appeared significant on particle size: HA850
permitted to obtain microspheres with larger D(0.5) and D [4,3], lower
polydispersity index (PI) (p b 0.05) and higher encapsulation efficiency.
Results were well correlated with the rheometric study, since
HA600 solutions, less viscous, led to smaller particles with a higher
polydispersity index (p b 0.05). Ré et al., who studied the influence
of the liquid properties on the physical properties of spray-dried
microparticles, reported similar observations: larger droplets were
formed by increasing the liquid viscosity and surface tension [33].
Given that the presence of EB had a small influence on HA600 and
HA850 solutions viscosity, it induced a slight decrease in particle
sizes and an increase of PI when comparing solutions of the same
polymer with or without EB.
Prior in vitro studies, the stability of HA600 andHA850microspheres
upon rehydration was explored by following their swelling with time
after immersion in Tris buffer at pH 7.4 (Fig. 7). Both formulations
presented the same rehydration profile, consisting in a rapid liquid ab-
sorption followed by a plateau and a progressive loss of weight due to
microspheres disintegration. HA850 microspheres swelling was faster:
they reached 2000% within the first 2 minutes, while HA600 micro-
spheres reached 1200% after 3 hours. Progressively, HA microspheres
became a loose gel before dissolving completely into the medium after
22 hours and 29 hours of immersion for HA600 and HA850 micro-
spheres, respectively. HA850 microspheres higher resistance resulted
from HA higher molecular weight. Regarding all the results, HA850 was
selected to test its in vitro release abilities.
3.3. In vitro release of EB from HA850 microspheres (HA), microspheres
loaded cements (MC-HA) and reference mineral cements (MC)
As an example, HA microspheres were incorporated in a mixed
calcium carbonate–calcium phosphate cement (further called MC:
mineral cement). In vitro release experiments were conducted on
HA, MC-HA and MC materials at 37 °C, in Tris buffer at pH 7.4, using
European Pharmacopoeia flow-through cells. Results are presented in
Fig. 8. Microspheres, microspheres loaded and reference cements led
to different release profiles. In the case of HA microspheres, EB release
was fast: it reached 79% in 7.5 hours and was complete in a lag time
of 30 hours. This result is in agreement with HA microspheres stability
in solution (Fig. 7). Bothmaterials (MC andMC-HA) exhibited sustained
release profiles, which appeared superimposable on the first 7.5 hours,
clearly showing that themineral matrix and its porosity were the limit-
ing factors of the release on the first hours. EB release at this time was
33.5% for MC-EB and 32.6% for MC-HA-EB. After 7.5 hours, the EB
release from reference cement remained significantly higher than
that of microspheres loaded cement, which appeared sustained. Only
57.7% of EB was released after 47 hours in the case of MC-HA-EB.
The shapes of the curves, combined with the mathematical ana-
lysis of the data, clearly show that the drug release modalities were
complex, and different in the three cases. The resulting kinetic pa-
rameters estimated from Higuchi and Weibull models (see Material
and methods) are presented in Table 3.
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Fig. 5. Influence of EB addition on the viscosity of HA solutions at various concentrations
(■, full line: H850; ▲, dotted line: HA850-EB).
Table 2
Main characteristics of the HA solutions (composition, viscosity) and resulting HA micro-
spheres after spray-drying experiments (yield, encapsulation efficiency, morphology and
granulometry).
Samples HA600 HA600-EB HA850 HA850-EB
HA concentration (g/L) 4 4 4 4
EB/HA ratio (% w/w) – 12.5 – 12.5
Viscosity (mPa s)a 22.4 20.9 27.8 18
Spray-drying conditions
Yield (%)b 37 45 27 46
Encapsulation efficiency (%)c – 89 – 93
Morphology Spherical
shape
Spherical
shape
Spherical
shape
Spherical
shape
D (0.5) (μm) 10.2 ± 0.2 8.7 ± 0.1 28.8 ± 0.2 18.1 ± 0.7
D [4.3] (μm) 13.8 ± 0.3 12.8 ± 0.3 37.3 ± 2.9 25.8 ± 4.1
PId 2.9 ± 0.0 3.3 ± 0.0 2.3 ± 0.1 2.8 ± 0.1
a Viscosity values for a shear rate of 1000 s−1.
b Ratio between microspheres collected at the end of the spray-dryer cyclone and the
initial quantity of nonvolatile matter (polysaccharide and EB) in solution.
c Determined by visible spectrometry at 528 nm.
d Polydispersity index corresponding to (D(0.1) − D(0.9))/D(0.5).
Table 3
Release kinetics parameters of EB release from HA850 microspheres (HA-EB), HA850
microspheres loaded cement (MC-HA-EB) and reference mineral cement (MC-EB).
Sample name AH-EB MC-HA-EB MC-EB
Synthesis
Ratio HA/solid phase (% w/w) – 10 –
Ratio EB/solid phase (% w/w) 10 1 1
Release properties
Higuchi model
KH dissolution constant (h
−1/2) 0.233 0.078 0.116
Coefficient of determination r2 0.986 0.971 0.999
Weibull model
Q0 93 65 70
B 0.77 0.41 0.57
tlag (hour) 0.088 0.14 0
tscale (hour) 3.29 11.59 6.99
Coefficient of determination r2 0.998 0.995 0.997
Dissolutive model
KDiff −0.2049 −0.0193 −0.0324
Coefficient of determination r2 0.998 0.891 0.982
Higuchi model fitted well EB delivery from reference cement, with a
coefficient of determination of 0.999. This is not surprising as Higuchi
model is currently used to interpret drug release profiles from calcium
phosphate cements (see Ref. [14] for review). Mixed calciumphosphate
and calcium carbonate cements are highly porous materials due to the
free spaces between precipitated crystals, with pore size in the nano/
micrometric range [34]. The reference mineral cement, initially consti-
tuted of platelets of brushite (B) and lentils of vaterite (V), is shown
on Fig. 9C. In vivo, these cements resorption rate is higher than that
of usual calcium phosphate cements because of the higher solubility of
the CaCO3metastable phase, vaterite, remaining in the cement final com-
position [26]. However, since their rate of degradation can be considered
much lower than the rate of drug liberation, thesemineral cements canbe
ascribed to the category of nonswellable monolithic systems. As a conse-
quence, drug release is mainly controlled by drug diffusion through min-
eral matrix in agreement with the Higuchi model.
Higuchi model did not fit well with HA-EB and MC-HA-EB curves,
except on the first hours of the experiment. In order to better under-
stand the releasemechanisms, theWeibull model was applied. This em-
pirical model can be used to describe release diffusion mechanisms
during the drug transport throughmicroparticles [29]. Simple interpre-
tations of the exponent b and the timescale tscale values give indica-
tions on the possible drug release mechanism. A pure Fick diffusion
mechanism corresponds to b = 1. Here, all the curves were fitted
with functions using b b 1. The release mechanisms might thus be
ascribed to diffusion in disordered media (with irregular porosity
leading to variations in the diffusion coefficient) [35] and/or to diffu-
sion associated to other phenomena like erosion of the matrix [36].
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Fig. 7. HA microspheres stability in Tris buffer 0.1 M pH 7.4 as a function of time and HA
average molecular weight (●, dotted line: HA600; ■, full line: HA850). Error bars repre-
sent the standard deviation for three measurements.
Fig. 6. SEM micrographs and granulometric distributions of HA and HA-EB microspheres (magnification ×2000).
In case of HA-EB microspheres, the release kinetics was fast (small
tscale and tlag values). This is the direct consequence of the diffusion of
the drug through HA particles and gel before complete destructuration.
Because hyaluronic acid has carboxyl and hydroxyl groups which can
bond with water, the hydrophilic surface is expected to reduce the
contact angle, and lead to an increased wettability of the encapsulated
molecule, resulting in an improved dissolution [6,5]. A coefficient of de-
termination of 0.998was also obtained by plotting the linear formof the
third semi-empirical equation (dissolutive release mechanism), clearly
showing that EB release from microspheres alone is mainly controlled
by HA matrix destructuration upon rehydration.
When HAmicroparticles and mineral cement were associated (MC-
HA-EB), EB release appeared to slow down after the first 7.5 hours
(high tscale value). The profile presented a tlag and tscale value in the
range of 0.14 and 11.59 hours respectively. However, the coefficient of
determination of the Weibull modelization was only 0.995, clearly
showing that EB release from MC-HA was complex and probably the
combination of several phenomena occurring successively. The release
profile can be considered in two stages. On the first 7.5 hours, the part
of EB released by the HA gel during cement preparation, setting and
hardening diffuses freely out of the cement, rending MC-EB and MC-
HA-EB release profiles very similar. But during the following hours, EB
release rate was significantly slowed in the case of the composite
cement. This could be explained by HA microspheres behavior upon
rehydration. When hydrophilic polymer based microspheres, such as
hyaluronan, are immersed in an aqueous medium, they swell and
form a gel diffusion layer that hampers the outward transport of
the drug within the matrix, hence producing a controlled release ef-
fect [37]. We already observed a similar phenomenon with pectin
microspheres–calcium phosphate composite cement [18]. Upon re-
hydration, HA microspheres become a loose gel which is quite diffi-
cult to preserve upon drying for MEB observation. For this reason,
HA presence in composite can only be detected as strands mapping
mineral particles, these strands being located in specific areas corre-
sponding to initial microspheres location. At a magnification of
×500, “prints” of HA microspheres can be seen within the mineral
cement (Fig. 9A, indicated by dotted circles). HA strands, at the bot-
tom of microsphere prints, can be evidenced at higher magnification
(Fig. 9B). HA presence within the mineral matrix pores, invading
spaces between brushite platelets and vaterite lentils particles, could
explain the slowed erythrosin B release from the composite cement,
when compared to reference cement.
4. Conclusion
As a conclusion, the feasibility of introducing HA microspheres in a
mineral bone cement, in order to modify its release properties, was
demonstrated. Spray-drying permitted a one-pot synthesis, avoiding
Fig. 9. SEMmicrographs of: A: HA850microspheres loaded cement (MC-HA-EB; magnifi-
cation ×500); B: HA850microspheres loaded cement (MC-HA-EB;magnification ×2000);
C: reference mineral cement (MC-EB; magnification ×2000). In A and B micrographs, the
presence of hyaluronic acid within the mineral matrix is indicated by dotted circles. In C
micrograph, platelets of brushite and lentils of vaterite are identified by a B and a V letter,
respectively.
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Fig. 8. Cumulative in vitro EB release in Tris buffer pH 7.4 at 37 °C from HA850 micro-
spheres (HA-EB: ■, dotted line), HA850 microspheres loaded cement (MC-HA-EB: ▲, full
line) and reference mineral cement (MC-EB: ●, dotted line). Error bars represent the
standard deviation for threemeasurements; lines are obtained by fitting the experimental
data points.
time-consuming steps and the use of harsh solvents. The process, com-
patible with on-line continuous production and easily scaled up, has
been optimized to obtain reproduciblemicroparticleswith size distribu-
tions adapted for the formulation of an injectable bone cement. HA
molecular weight and concentration appeared to have a significant influ-
ence on process parameters and resulting microspheres. HA850 micro-
spheres degraded in 30 hours when immersed in a buffer medium.
However, the introduction of HA microspheres in a mineral cement led
to a sustained release, due to HA gel formation within the pores of the
mineralmatrixwhich decreases the diffusion rate. Hyaluronic acidmicro-
spheres could be of particular interest to formulate bone cements with
extended ability to release active compounds.
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